PTGX
Protagonist Therapeutics, Inc.
Biotechnology · Healthcare · United States
144.34
close · 2026-10-29
value
3
cheaper than peers3
quality
95
stronger fundamentals95
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 11.09× | 20 |
| price to sales | 127.45× | 13 |
| forward P/E | 2471.15× | 1 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.5% | 90 |
| revenue growth | 99.0% | 77 |
| operating margin | -6.5% | 75 |
| return on equity | -17.1% | 74 |
4 of 4 measures available
Facts
| market cap | $9B |
| free cash flow | -$77.7M |
| employees | 131 |
| first trade | 2016-08-11 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -2.05 | 4.23 | -1.39 | -2.60 | not reported |
| free cash flow | $56.1M | $182.8M | -$70.8M | -$108.9M | not reported |
| net income | -$130.1M | $275.2M | -$79.0M | -$127.4M | not reported |
| revenue | $46.0M | $434.4M | $60.0M | $26.6M | not reported |
| unusual items | not reported | not reported | not reported | $0 | $0 |